Search form
Search
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
contact us
You are here
Home
»
companies
» lanadelumab
lanadelumab
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Seeking Alpha
Shire
HAE
SHP643
lanadelumab
Flag link:
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Shire
lanadelumab
DX-2930
HAE
Cinryze
Dyax
Flag link:
Shire Rises on Encouraging Angioedema Results
Shire Rises on Encouraging Angioedema Results
TheStreet.com
Shire
angioedema
lanadelumab
Flag link:
